R-Ginsenodie Rg3

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 540173

CAS#: 38243-03-7

Description: R-Ginsenodie Rg3 γ2 GABA-A receptor agonist, 7.1 K+ channel activator, α10 nAChR antagonist found in Panax. It exhibits a wide variety of biological activities, including decreasing expression of pro-inflammatory cytokines, reducing oxidative stress, and inhibiting tubular formation and migration of endothelial progenitor cells.


Chemical Structure

img
R-Ginsenodie Rg3
CAS# 38243-03-7

Theoretical Analysis

MedKoo Cat#: 540173
Name: R-Ginsenodie Rg3
CAS#: 38243-03-7
Chemical Formula: C42H72O13
Exact Mass: 784.50
Molecular Weight: 785.020
Elemental Analysis: C, 64.26; H, 9.25; O, 26.49

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym:

IUPAC/Chemical Name: (2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5S,6R)-4,5-dihydroxy-2-(((3R,5S,8R,9R,10R,12S,13R,14R,17S)-12-hydroxy-17-((S)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,10,13,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

InChi Key: VOWJAFYNABYJKY-JLBFJOLRSA-N

InChi Code: InChI=1S/C42H72O13/c1-21(2)10-9-15-41(7,51)27-13-17-40(6)22-11-12-26-38(3,4)29(14-16-39(26,5)23(22)18-28(45)42(27,40)8)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23-,24-,25-,26-,27-,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,39-,40-,41+,42+/m1/s1

SMILES Code: CC1(C)[C@H]2CC[C@H]3[C@@]4(C)CC[C@H]([C@@](C)(O)CC/C=C(C)\C)[C@@]4(C)[C@@H](O)C[C@H]3[C@@]2(C)CC[C@H]1O[C@H]5[C@@H]([C@H]([C@@H]([C@@H](CO)O5)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@@H](CO)O6)O)O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 785.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sun C, Gao W, Zhao B, Cheng L. Optimization of the selective preparation of 20(R)-ginsenoside Rg3 catalyzed by d, l-tartaric acid using response surface methodology. Fitoterapia. 2013 Jan;84:213-21. doi: 10.1016/j.fitote.2012.11.011. Epub 2012 Dec 3. PubMed PMID: 23219978.

2: Geng L, Fan J, Gao QL, Yu J, Hua BJ. [Preliminary study for the roles and mechanisms of 20(R)-ginsenoside Rg3 and PEG-PLGA-Rg3 nanoparticles in the Lewis lung cancer mice]. Beijing Da Xue Xue Bao. 2016 Jun 18;48(3):496-501. Chinese. PubMed PMID: 27318914.

3: Keung MH, Chan LS, Kwok HH, Wong RN, Yue PY. Role of microRNA-520h in 20(R)-ginsenoside-Rg3-mediated angiosuppression. J Ginseng Res. 2016 Apr;40(2):151-9. doi: 10.1016/j.jgr.2015.07.002. Epub 2015 Jul 29. PubMed PMID: 27158236; PubMed Central PMCID: PMC4845046.

4: Yoon SJ, Park JY, Choi S, Lee JB, Jung H, Kim TD, Yoon SR, Choi I, Shim S, Park YJ. Ginsenoside Rg3 regulates S-nitrosylation of the NLRP3 inflammasome via suppression of iNOS. Biochem Biophys Res Commun. 2015 Aug 7;463(4):1184-9. doi: 10.1016/j.bbrc.2015.06.080. Epub 2015 Jun 15. PubMed PMID: 26086107.

5: Lim CJ, Choi WY, Jung HJ. Stereoselective skin anti-photoaging properties of ginsenoside Rg3 in UV-B-irradiated keratinocytes. Biol Pharm Bull. 2014;37(10):1583-90. Epub 2014 Jul 24. PubMed PMID: 25056231.

6: Wu R, Ru Q, Chen L, Ma B, Li C. Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22-bearing mice. J Food Sci. 2014 Jul;79(7):H1430-5. doi: 10.1111/1750-3841.12518. PubMed PMID: 25041540.

7: Luo Y, Zhang P, Zeng HQ, Lou SF, Wang DX. Ginsenoside Rg3 induces apoptosis in human multiple myeloma cells via the activation of Bcl-2-associated X protein. Mol Med Rep. 2015 Sep;12(3):3557-62. doi: 10.3892/mmr.2015.3802. Epub 2015 May 19. PubMed PMID: 25998024.

8: Sun CP, Gao WP, Zhao BZ, Cheng LQ. Conversion of protopanaxadiol type saponins to ginsenoside Rg3 by lemon. Nat Prod Commun. 2012 Sep;7(9):1155-6. PubMed PMID: 23074894.

9: Zhang W, Wang X, Zhang M, Xu M, Tang W, Zhang Y, Lu L, Gao J, Gao S. Intranasal delivery of microspheres loaded with 20 (R)-ginsenoside Rg3 enhances anti-fatigue effect in mice. Curr Drug Deliv. 2016 Nov 9. [Epub ahead of print] PubMed PMID: 27834150.

10: Zhang LP, Jiang YC, Yu XF, Xu HL, Li M, Zhao XZ, Sui DY. Ginsenoside Rg3 Improves Cardiac Function after Myocardial Ischemia/Reperfusion via Attenuating Apoptosis and Inflammation. Evid Based Complement Alternat Med. 2016;2016:6967853. doi: 10.1155/2016/6967853. Epub 2016 Dec 26. PubMed PMID: 28105061; PubMed Central PMCID: PMC5220470.

11: Yu X, Xu H, Hu M, Luan X, Wang K, Fu Y, Zhang D, Li J. Ginsenoside Rg3 bile salt-phosphatidylcholine-based mixed micelles: design, characterization, and evaluation. Chem Pharm Bull (Tokyo). 2015;63(5):361-8. doi: 10.1248/cpb.c15-00045. PubMed PMID: 25948329.

12: Wang J, Cui C, Fu L, Xiao Z, Xie N, Liu Y, Yu L, Wang H, Luo B. Genomic expression profiling and bioinformatics analysis on diabetic nephrology with ginsenoside Rg3. Mol Med Rep. 2016 Aug;14(2):1162-72. doi: 10.3892/mmr.2016.5349. Epub 2016 May 27. PubMed PMID: 27279428; PubMed Central PMCID: PMC4940079.

13: Zhang W, Bai X, Wang Y, Zhao B, Zhao Y, Hou W, Jin Y, Zhao D. SERS study of different configurations of pharmaceutical and natural product molecules ginsenoside Rg3 under the interaction with human serum albumin on simple self-assembled substrate. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jan 3;117:210-5. doi: 10.1016/j.saa.2013.07.087. Epub 2013 Aug 12. PubMed PMID: 23994676.

14: Wang L, Li X, Song YM, Wang B, Zhang FR, Yang R, Wang HQ, Zhang GJ. Ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to γ-radiation by targeting the nuclear factor-κB pathway. Mol Med Rep. 2015 Jul;12(1):609-14. doi: 10.3892/mmr.2015.3397. Epub 2015 Feb 27. PubMed PMID: 25738799.

15: Shan X, Tian LL, Zhang YM, Wang XQ, Yan Q, Liu JW. Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death. Int J Oncol. 2015 Aug;47(2):701-9. doi: 10.3892/ijo.2015.3057. Epub 2015 Jun 18. PubMed PMID: 26094873.

16: Zhang YH, Li HD, Li B, Jiang SD, Jiang LS. Ginsenoside Rg3 induces DNA damage in human osteosarcoma cells and reduces MNNG-induced DNA damage and apoptosis in normal human cells. Oncol Rep. 2014 Feb;31(2):919-25. doi: 10.3892/or.2013.2914. Epub 2013 Dec 11. PubMed PMID: 24337872.

17: Teng S, Wang Y, Li P, Liu J, Wei A, Wang H, Meng X, Pan D, Zhang X. Effects of R type and S type ginsenoside Rg3 on DNA methylation in human hepatocarcinoma cells. Mol Med Rep. 2017 Apr;15(4):2029-2038. doi: 10.3892/mmr.2017.6255. Epub 2017 Feb 28. PubMed PMID: 28260016; PubMed Central PMCID: PMC5364960.

18: Guo JQ, Zheng QH, Chen H, Chen L, Xu JB, Chen MY, Lu D, Wang ZH, Tong HF, Lin S. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE cadherin/EphA2/MMP9/MMP2 expression. Int J Oncol. 2014 Sep;45(3):1065-72. doi: 10.3892/ijo.2014.2500. Epub 2014 Jun 16. PubMed PMID: 24938458.

19: Wei X, Su F, Su X, Hu T, Hu S. Stereospecific antioxidant effects of ginsenoside Rg3 on oxidative stress induced by cyclophosphamide in mice. Fitoterapia. 2012 Jun;83(4):636-42. doi: 10.1016/j.fitote.2012.01.006. Epub 2012 Jan 28. PubMed PMID: 22310172.

20: Shan X, Aziz F, Tian LL, Wang XQ, Yan Q, Liu JW. Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression. Int J Oncol. 2015 Apr;46(4):1667-76. doi: 10.3892/ijo.2015.2886. Epub 2015 Feb 10. PubMed PMID: 25672851.